Vertex’s VX-548 Phase 3 programme in acute pain yields positive results
Vertex Pharmaceuticals said that the Phase 3 programme for its selective NaV1.8 inhibitor VX-548 in the treatment of moderate-to-severe acute pain has yielded positive results. The programme comprised